Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06716658
- Conditions
- Cutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Hematologic Diseases, +22 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital, China Tianjin, Tianjin Municipality, China
- Institute of Hematology & Blood Diseases Hospital Tianjin, China